PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hendrick J. Boot et al.

Serial No.: To be assigned

Filed: January 14, 2002

For: MOSAIC INFECTIOUS BURSAL DISEASE VIRUS VACCINES

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-5238US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL 740516437 US

Date of Deposit with USPS: January 14, 2002

Person making Deposit: Orlena Howell

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Before calculation of the filing fee, please revise the above-identified application as follows:

IN THE CLAIMS:

4. (Amended) The rIBDV of claim 2 wherein said rIBDV is essentially incapable of growing in a CEF cell, a VERO cell or a QM5 cell.

5. (Amended) The rIBDV of claim 3 wherein the rIBDV's VP2 protein sequence has no asparagine at amino acid position 279.

7. (Amended) The rIBDV of claim 3 wherein the protein VP2 has no threonine at amino acid position 284.

12. (Amended) The method according to claim 10 wherein said first cell is a non-bursa cell derived cell.

13. (Amended) The method according to claim 12 wherein said second cell is a Bursa-cell derived cell.

14. (Amended) The method according to claim 13 wherein said first cell, such as a CEF cell, a VERO cell or a QM5 cell, is non-permissive for vvIBDV.

15. (Amended) The method according to claim 14 wherein said first cell has additionally been provided with a helper virus or a viral protein derived from a helper virus.

17. (Amended) The method according to claim 16 wherein said rIBDV has at least retained the incapacity to substantially be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO, a QM5 and CEF cell.

18. (Amended) The method according to claim 17 wherein said permissive second cell is a primary bursa cell.

19. (Amended) The method according to claim 18 wherein said rIBDV comprises at least a nucleic acid derived from at least a part of genome segment A of vvIBDV.

21. (Amended) The method according to claim 20 wherein said rIBDV comprises at least a nucleic acid derived from a serotype II IBDV.

22. (Amended) The method according to claim 21 wherein said rIBDV is lacking at least one immunodominant epitope specific for a serotype I IBDV.

25. (Amended) The mIBDV of claim 24 wherein said mIBDV is unable to be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO cell, a QM5 cell, and a CEP cell.

26. (Amended) The mIBDV of claim 25 wherein said mIBDV is able to be propagated on a vvIBDV permissive cell.

27. (Amended) The mIBDV of claim 26 wherein at least one of said isolates is a serotype II IBDV.

28. (Amended) The mIBDV of claim 27 lacking at least one immunodominant epitope specific for a serotype I IBDV.

29. (Amended) A vaccine comprising the rIBDV of claim 2.

Remarks

No new matter has been added. Applicants request entry of the foregoing amendment prior to calculation of the filing fee and examination of the application on the merits. All amendments are made without prejudice or disclaimer.

Respectfully submitted,

Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: January 14, 2002

APPENDIX A

Version with markings to show changes made

4. (Amended) The rIBDV of [any one of claims 1 to 3] claim 2 wherein said rIBDV is essentially incapable of growing in a CEF cell, a VERO cell or a QM5 cell.

5. (Amended) The rIBDV of [any one of claims 1 to 4] claim 3 wherein the rIBDV's VP2 protein sequence has no asparagine at amino acid position 279.

7. (Amended) The rIBDV of [any one of claims 1 to 6] claim 3 wherein the protein VP2 has no threonine at amino acid position 284.

12. (Amended) The method according to claim 10 [or 11] wherein said first cell is a non-bursa cell derived cell.

13. (Amended) The method according to [any one of claims 10 to] claim 12 wherein said second cell is a Bursa-cell derived cell.

14. (Amended) The method according to [any one of claims 10 to] claim 13 wherein said first cell, such as a CEF cell, a VERO cell or a QM5 cell, is non-permissive for vvIBDV.

15. (Amended) The method according to [any one of claims 10 to 14] claim 14 wherein said first cell has additionally been provided with a helper virus or a viral protein derived from a helper virus.

17. (Amended) The method according to [any one of claims 10 to] claim 16 wherein said rIBDV has at least retained the incapacity to substantially be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO, a QM5 and CEF cell.

18. (Amended) The method according to [any one of claims 10 to] claim 17 wherein said permissive second cell is a primary bursa cell.

19. (Amended) The method according to [any one of claims 10 to] claim 18 wherein said rIBDV comprises at least a nucleic acid derived from at least a part of genome segment A of vvIBDV.

21. (Amended) The method according to [any one of claims 10 to] claim 20 wherein said rIBDV comprises at least a nucleic acid derived from a serotype II IBDV.

22. (Amended) The method according to [any one of claims 10 to] claim 21 wherein said rIBDV is lacking at least one immunodominant epitope specific for a serotype I IBDV.

25. (Amended) The mIBDV of claim [23 or] 24 wherein said mIBDV is unable to be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO cell, a QM5 cell, and a CEP cell.

26. (Amended) The mIBDV of [any one of claims 23 to] claim 25 wherein said mIBDV is able to be propagated on a vvIBDV permissive cell.

27. (Amended) The mIBDV of [any one of claims 23 to] claim 26 wherein at least one of said isolates is a serotype II IBDV.

28. (Amended) The mIBDV of [any one of claims 23 to] claim 27 lacking at least one immunodominant epitope specific for a serotype I IBDV.

29. (Amended) A vaccine comprising the rIBDV of [any one of claims 1 to 9 or the mIBDV of any one of claims 23 to 28] claim 2.